April 13 (Reuters) - Alkermes Inc. (ALKS.O) said the U.S. Food and Drug Administration approved a new dose of risperidone for the treatment of schizophrenia.
The drug, manufactured by Alkermes and marketed in the U.S. by Janssen L.P., will allow more options to individualize treatment, the company said in a statement. (Reporting by Anant Vijay Kala in Bangalore)
WASHINGTON (Reuters) -- U.S. Treasury pay czar Kenneth Feinberg has approved compensation plans for several firms receiving assistance from Uncle Sam.
The bubble has burst and the economy is bottoming out. So why are Americans still hesitant to buy new homes? Full Article
Ever the contrarian, fund manager Maura Shaughnessy finds ways to make money amid the market meltdown -- even if it means kicking executives in the shin. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
